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Background: The epidermal growth factor receptor (EGFR) has 
been implicated in pre-clinical models of non small cell lung cancer 
(NSCLC) as contributing to angiogenesis, metastasis, and resistance 
to radiation and chemotherapy, while its over expression is associ-
ated with poorer outcome. Nimotuzumab is a humanized monoclonal 
antibody (mAb) directed against the extracellular domain of human 
EGFR1 that does not exhibit the typical skin and GI toxicity seen with 
other agents in this class. Nimotuzumab administered concurrently with 
radiotherapy is a well-tolerated combination that may enhance radio-
curability of unresectable head and neck neoplasms. Here we outline 
the preliminary results of a phase I/II trial of this agent given concur-
rently with palliative radiation in patients with NSCLC.
Methodology: Eligible patients (age >18 years; histologically or cyto-
logically conﬁrmed Stage IIB, III or IV NSCLC; unsuitable for radical 
radiation or chemo-radiation; measurable disease within the planned 
radiation ﬁeld) received nimotuzumab as a 30 minute IV infusion 
weekly on weeks 1 - 8 starting on day 1, 2 to 6 hrs after radiation (30 
Gy 10 fractions, Monday to Friday). If response or disease stability was 
observed, nimotuzumab was continued every other week starting from 
week 10 until progression or toxicity.
Results: 6 patients (age 60 - 81; median age 76) have been enrolled in 
the 1st cohort (100mg) of the study. Stages at diagnosis were IIIA - 2; 
IIIB - 3; IV - 1. To date 2 PR, two SD, and one DP have been observed. 
Median overall survival of the group is 26 weeks. Two patients have 
died of progressive disease and two patients have withdrawn from the 
study. Two SAE’s have been reported, but neither one has been caus-
ally attributable to Nimotuzumab. There has been a notable absence of 
grade III IV rash or diarrhea in this cohort. 
Patient # Age
NSCLC 
Stage
Prior 
Therapy
Best 
Response
Survival from  
1st dose (Wks)
Current 
Status
1 76 IIIA None PR 51w+ Withdrawn
2 81 IIIB None SD 39+ Ongoing
3 * 74 IIIA Chloram-bucil NA NA Withdrawn
4 76 IIIB None SD 24 Died 
5 67 IIIB None PR 14 Died 
6 60 IV None DP 17+ Ongoing
*Not eligble for the study because of concurrent CLL
Conclusion: Nimotuzumab administered concurrently with radiation is 
well tolerated at this dose in NSCLC patients. Although it speciﬁcally 
targets the EGF receptor, the absence of rash and diarrhea makes it 
therapeutically attractive. Four patients have now been enrolled in the 
second cohort (200mg) and the updated results will be presented at the 
congress.
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Sodiumselenite in the treatment of lung cancer
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Option: Resistance to chemotherapy is a major obstacle to improved 
survival in NSCLC and SCLC. In vitro, selenite in fairly moderate con-
centration kills most lung cancer cell lines. We have started a clinical 
study on selenite to patients with chemotherapy resistant lung cancer.
Background. In vitro studies of lung cancer, mesotelioma and leuce-
mia cell lines have demonstrated that sodiumselenite in doses above 5 
micromol/L induces apoptosis in most cell lines. It is accomplished in 
a different manner compared to clinically used cytotoxic drugs, since 
there seems to be especially the drug resistant cell lines that are sensi-
tive to selenite. An enzyme thioredoxin reductase seems to be involved 
in the process. High doses of this enzyme protects against the oxida-
tive stress produced by cytotoxic drugs but not to selenite. An additive 
effect of selenite and chemotherapy is also seen. One further ﬁnding 
makes sodium selenite interesting in this context. During the seven-
ties sodiumselenite with Se75 was used as a tumor seeking tracer for 
scintigraphy, making it probable that a favourable Se gradient might be 
found clinically.
Patients and methods: The maximal tolerable dose (MTD) of sodium 
selenite is not known. Therefore we have started with an ordinary phase 
I study to deﬁne MTD. Selenium is given in daily doses during a ﬁve 
week period. After that a response evaluation is performed and patients 
not acquiring a complete response are two weeks after the selenite stop 
given chemotherapy. When MTD is found we will proceed with an 
ordinary phase II study with response as the primary endpoint. Serum 
and tumour samples will be taken both in the phase I and II studies to 
study dose-effect relationship and to seek predictive factors among 
others with microarray expression in untreated and treated tumour cells.
Results: The ﬁrst patient in the phase I study has just gone through the 
selenite treatment without side effects. The next two on the ﬁrst treat-
ment level are just going to start. Further results from the phase I study 
will be presented at the meeting.
Conclusion: If selenite could be given in sufﬁcient doses to kill tumor 
cells with acceptable side effects it would probably be a cheap and use-
ful complement to cytotoxic drugs. 
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Background: Combining existing lung cancer therapies with novel 
agents that interfere with major signaling pathways is a promising ap-
